Mizuho starts Castle Biosciences at outperform with $60 target
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Mizuho has initiated coverage on Castle Biosciences (NASDAQ:CSTL) with an "outperform" rating and a $60 price target, suggesting a significant upside. The company has a consensus "Moderate Buy" rating from analysts and recently surpassed quarterly earnings and revenue expectations. Despite positive analyst sentiment, insiders have sold a notable amount of stock in the last 90 days.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.